Anti-Rat β-2-Microglobulin (Clone 4C9) – Purified No Carrier Protein

Anti-Rat β-2-Microglobulin (Clone 4C9) – Purified No Carrier Protein

Product No.: B615

- -
- -
Clone
4C9
Target
β-2-Microglobulin
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
β2M
Isotype
Mouse IgG1 κ
Applications
FA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Rat
Host Species
Mouse
Immunogen
Soluble neonatal Fc receptor (FcRn)
Product Concentration
≥1.0 mg/ml
Purity
≥90% monomer by analytical SEC and SDS-Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
State of Matter
Liquid
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
FA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
4C9 activity is directed against rat β-2-microglobulin that is free or complexed with the FcRn heavy chain.
Background
Neonatal Fc receptor (FcRn) is a 52 kDa membrane bound heterodimeric glycoprotein composed of a heavy and light chain, with the latter being β-2-microglobulin1. FcRn plays a role in the regulation of IgG catabolism and is located in the endosome where it binds to Fc and IgG. β-2- microglobulin also associates with class I major histocompatibility complex molecules, which are structurally similar to FcRn2. In this capacity, β-2-microglobulin plays an important role in tumor antigen presentation and immune surveillance3.

4C9 was generated by immunizing BALB/c mice with soluble FcRn2. Splenocytes were fused with HL-1 murine myeloma cells. 4C9 is able to bind to β-2-microglobulin as well as FcRn heterodimers in ELISA tests, can immunoprecipitate soluble FcRn heterodimers, and can also stain lipid-linked rat β-2-microglobulin (β2m-DAF), truncated FcRn heavy chain paired with β2m-DAF, and lipid-linked FcRn heavy chain paired with unaltered β-2-microglobulin.

4C9 blocks binding of IgG to FcRn in vitro2 and FcRn blockade has been shown to have a positive effect on IgG-mediated autoimmune diseases1. In support of this, 4C9 induces a transient and dose-dependent increase in the elimination of exogenously administered antimethotrexate IgG in rats4.
Antigen Distribution
β-2-microglobulin has cytoplasmic and membranous expression in most cell types and can be secreted to blood.
Ligand/Receptor
Leukocytes, platelets, endothelial cells and epithelial cells
NCBI Gene Bank ID
Research Area
Immunology

References & Citations

1 Low SC, Mezo AR. AAPS J. 11(3):432-434. 2009.
2 Raghavan M, Chen MY, Gastinel LN, et al. Immunity. 1(4):303-315. 1994.
3 Wang H, Liu B, Wei J. Cancer Lett. 517:96-104. 2021.
4 Getman KE, Balthasar JP. J Pharm Sci. 94(4):718-729. 2005.
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.